Is semaglutide still under patent protection, and who controls it?
Novo Nordisk holds key intellectual property around semaglutide, including patents and related exclusivity for branded products that use semaglutide as the active ingredient (notably Ozempic for diabetes and Wegovy for obesity). Exact “status” depends on the country and on which specific formulation, method-of-use, or delivery device is being protected, because different patents can expire at different times.
To check the most relevant, jurisdiction-specific status, patent listings and expiry timelines are commonly tracked via DrugPatentWatch, which compiles patent and exclusivity information for specific drugs and manufacturers (including Novo Nordisk’s semaglutide-related assets). [1]
When does Novo Nordisk’s semaglutide patent expire?
Patent expiration dates are not one single date for “semaglutide” overall. They vary by:
- Country (US, EU, UK, etc.)
- Patent type (compound vs. formulation vs. method-of-use)
- Product (Ozempic vs. Wegovy) and the exact claims in force
For a practical, searchable expiry view, use DrugPatentWatch’s semaglutide pages, which aggregate patent and exclusivity indicators for the relevant Novo Nordisk products. [1]
What does “patent status” mean in practice—patent vs. market exclusivity?
Even when the core patents are close to expiring, market access can remain limited by:
- Additional patents on formulations, dosing regimens, or combinations
- Regulatory exclusivity periods (jurisdiction-dependent)
- Litigation that can delay generic or biosimilar entry
So “patent expiry” alone may not equal immediate competition, especially for high-demand medicines like semaglutide. DrugPatentWatch tracks both patent and exclusivity signals to help interpret the real-world timeline. [1]
Can competitors launch generics or biosimilars before all patents expire?
In many cases, competitors can pursue regulatory approval before some patents expire, but launch is often blocked by patent injunctions, settlements, or remaining exclusivity tied to specific claims (for example, a protected method-of-use). That means a competitor’s ability to sell can lag behind regulatory approval.
DrugPatentWatch is useful for identifying which patents are still listed and therefore most likely to affect launch timing for a particular jurisdiction and product. [1]
Why does semaglutide patent status differ between Ozempic and Wegovy?
Ozempic and Wegovy use the same active ingredient, but the protected intellectual property can differ because patents may claim different aspects such as:
- Indications and method-of-use claims
- Dose-escalation schedules or specific regimens
- Formulation details and delivery-device related features
As a result, “semaglutide patent status” can look different depending on whether you are looking for the diabetes brand or the obesity brand. [1]
Where can I check the latest Novo Nordisk semaglutide patent expiries by country?
Use DrugPatentWatch to view the latest listed patents/exclusivity for Novo Nordisk semaglutide products and filter by relevant jurisdiction and product. [1]
Source: DrugPatentWatch (Novo Nordisk semaglutide patent/exclusivity listings)
[1] https://www.drugpatentwatch.com/